

Table 14.3.1.37.4
Summary of Deep Vein Thrombosis up to 28 Days After Each Injection
Safety Set

After First Injection

	Placebo (N = 15162)	mRNA-1273 (N = 15184)
Number of Subjects Reporting Deep vein thrombosis, n (%)	2 (<0.1)	0
Number of Events	2	0
Onset Day		
Median	10.0	
Min, Max	9, 11	
Duration		
Median	166.5	
Min, Max	144, 189	

Deep vein thrombosis includes adverse events with preferred term of "Deep vein thrombosis".

MedDRA version 23.0.

Program Path: ¥¥wilbtia¥wilbtia01¥Moderna MODMRNA1273P301_U¥BLAYTLF¥t1403013704.sas 20DEC2021 16:47

Table 14.3.1.37.4
Summary of Deep Vein Thrombosis up to 28 Days After Each Injection
Safety Set

After Second Injection

	Placebo (N = 14631)	mRNA-1273 (N = 14731)
Number of Subjects Reporting Deep vein thrombosis, n (%)	1 (<0.1)	1 (<0.1)
Number of Events	1	1
Onset Day		
Median	16.0	27.0
Min, Max	16, 16	27, 27
Duration		
Median	176.0	186.0
Min, Max	176, 176	186, 186

Deep vein thrombosis includes adverse events with preferred term of "Deep vein thrombosis".

MedDRA version 23.0.

Program Path: ¥¥wilbtia¥wilbtia01¥Moderna MODMRNA1273P301_U¥BLAY¥TLF¥t1403013704.sas 20DEC2021 16:47